Excimer Laser for Vitiligo
Customize your policy alerts
Sign up for AmeriHealth Caritas Policy CCP.1303 alerts
Get alerted when Policy CCP.1303 changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage determinations for monochromatic excimer (308 nm) laser light therapy for localized vitiligo for AmeriHealth Caritas members and guides provider documentation and prior authorization expectations.
No material clinical or coverage changes in this revision.
Coverage Criteria for Excimer Laser Therapy
Initial therapy (medically necessary)
Covered when ALL of the following are met
Sources: Ludmann 2026; Taieb 2013
Treatment duration and stopping rules
Continuation criteria and stopping rules
Expert guidance: continue while repigmentation is occurring, up to 1–2 years (Taieb 2013).
Monochromatic excimer laser (308 nm) therapy for localized vitiligo is considered investigational / not medically necessary when any of the following stopping rules are met: no repigmentation within the first 12 weeks; an unsatisfactory response defined as <25% repigmentation after 24 weeks; or when treatment duration would exceed 104 weeks.
If the above stopping rules are satisfied, continuation of monochromatic excimer laser therapy is not supported by the policy and the service is considered investigational / not medically necessary.
Coding and Treatment Regimen
| 96999 | Unlisted special dermatological service or procedure |
Provider Actions, Prior Authorization, and Documentation
Prior authorization required when criteria met
Prior authorization is expected when excimer laser therapy (308 nm) is used for repigmentation of localized vitiligo that meets the medical necessity criteria (lesions on the face/neck; failure, intolerance, or contraindication to at least one topical corticosteroid and at least one topical calcineurin inhibitor; or to avoid/when NB-UVB is contraindicated). CPT code 96999 is commonly submitted for this service.
- Prior auth applies when all medical necessity criteria are met (face/neck lesions; prior failure/intolerance/contraindication to required topicals; or to avoid/when NB-UVB is contraindicated).
Required prior topical therapy
Require documentation of a prior trial of at least one topical corticosteroid and at least one topical calcineurin inhibitor; exceptions permitted only for documented intolerance or contraindication.
- At least one topical corticosteroid trial
- At least one topical calcineurin inhibitor trial
- Documented intolerance or contraindication if either topical agent was not used
Required documentation
Document lesion location (notably face and neck), prior use and failure/intolerance/contraindication to the required topicals, the rationale for choosing excimer versus other phototherapy, and the treatment schedule plus measured response (percent repigmentation) over treatment weeks.
- Location of lesions (face/neck emphasized)
- Details of prior topical therapy trials and any intolerance/contraindication
- Rationale for excimer laser instead of NB-UVB or other therapies
- Treatment schedule (frequency) and response tracking (repigmentation % across weeks)
Denial triggers
Treatment is considered investigational/not medically necessary and may be denied if stopping rules or unsatisfactory response criteria are met: no repigmentation within the first 12 weeks, <25% repigmentation after 24 weeks, or treatment duration exceeds 104 weeks.
- Discontinue/deny if no repigmentation within first 12 weeks
- Discontinue/deny if <25% repigmentation after 24 weeks
- Do not continue beyond 104 weeks
Background
Vitiligo is a chronic depigmenting condition characterized by focal loss of melanocytes and clinically evident white patches. Monochromatic excimer laser is a targeted phototherapy option used for limited patches; however, evidence and expert guidance emphasize predefined treatment trials and stopping rules to judge effectiveness and appropriateness of continued therapy.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.